Conclusions:
The sixth month of therapy is a crucial target for the management of PMR, because it can help to identify patients at greater risk of exacerbations, which may benefit from a tighter follow-up and a more aggressive therapeutic strategy. Among prognostic factors female sex and high CRP values at sixth months appear to be associated with higher relapse risk and a longer duration of treatment. Background: Granulomatosis with polyangiitis (GPA) is a granulomatous necrotizing vasculitis with high morbidity and mortality. Anti-neutrophil cytoplasmic antibody (ANCA) is a rvaluable diagnostic marker, however its titer lacks predictive value for the severity of organ involvement. Platelet to lymphocyte ratio (PLR) and mean platelet volume has been regarded as a potential marker in assessing systemic inflammation. Objectives: We aimed to investigate PLR and MPV as inflammatory marker in patients with GPA. Methods: GPA patients and age-sex matched healthy controls were included. Demographic, clinical and laboratory information were extracted from medical records. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white blood cell (WBC), platelets (PLT), lymphocyte and neutrophils counts and glomerular filtration rate (GFR) were recorded. PLR was calculated. Disease activity was assessed with Birmingham Vasculitis Activity Score for WG vasculitis (BVAS/WG). Results: 56 patients with GPA and 53 healty controls were included. Clinical characteristics and laboratory findings of the study population are shown in Table  1 . ESR, CRP, MPV and PLR were significantly higher in patients with GPA than controls. PLR positively correlated with ESR and CRP (r:0.389, p:0.005 and r:0.512 p<0.001, respectively). In contrast, MPV negatively correlated with ESR and CRP (r:-0.308, p:0.028 and r:-0.337 p:0.014, respectively). There were no significant correlation between PLR, MPV and BVAS/WG. Patients with renal involvement had statistically significantly higher PLR than patients without renal involvement (303.01±287.33 vs177.98 + 75.43, p: 0.020 respectively). Moreover PLR negatively correlated with glomerlar filtration rate (r:-0.266 and p:0.009). Receiver operating characteristic curve of PLR, ESR and CRP for differentiating renal involvement is presented in Figure 1 Background: GCA may be an interleukin-6 (IL-6) driven disease and IL-6 blockade is emerging as an exciting therapy of IL-6. 1 We measured serial IL-6 levels in new patients with GCA treated in an RCT of modified-release prednisone (MR) versus immediate-release prednisolone (IR) used in a tapering regimen conforming to BSR guidelines.
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Methods: Patients (n=12) were randomised into two treatment arms (7 MR, 5 IR) and followed up over 26 weeks. IL-6 samples were collected at 9am at weeks 4, 10, 18 and 26 and were measured using Beckman Coulter IL-6 immunoassay, validated in a controlled study according to ACB criteria. We also measured bone markers (CTX, P1NP, vitamin D), HbA1c, cortisol, ACTH and PTH. Results: Significantly higher overall mean IL-6 levels were seen in the IR arm (n=5) compared to MR (n=7) [unpaired two-tailed Student's t test]. IL-6 levels in both arms were lowest between weeks 4-10 and continued to decrease in the IR arm to week 26, whereas lower but constant levels were seen in the MR arm ( Figure) Mean CTX concentration was significantly higher at week 4 (M =0.29, SE =0.04) compared to Week 26 (M =0.13, SE =0.02) p=0.002. No significant difference was seen between treatment arms. Patients on MR had complete suppression of ACTH compared to IR (p<0.05) without a significant difference between groups in 9 am cortisol levels (p=0.3412). No significant differences were seen in levels of vitamin D, calcium, PTH, ESR, CRP, or HbA1c.
Conclusions:
Our study suggests that elevated levels of Il-6 are better suppressed by MR prednisone therapy compared to IR prednisolone in new GCA. Bone resorption marker CTX was significantly reduced in both treatment arms. ACTH suppression with MR prednisone may reflect a greater impact on the HPA axis although cortisol levels were not affected. Our findings suggest that MR prednisone may warrant further clinical trial investigation in GCA. (Table 1 ). All patients were treated with oral glucocorticoids (GC).As additional immunosuppressive agents, azathiopirine was given to 21 (40.4%) and pulse cyclophosphamide to 11 (21.2%) patients. Twenty-eight patients (53.9%) had follow-up of 28.6 months. Five (17.8%) patients relapsed during follow-up. While 3 relapses were major, 2 of them were minor relapses. At the last visit, disease status was evaluated as active or treatment failure by the treating physician in 6 (21.4%) patients. Mortality was 3.6% (n=1) during follow-up, due to pneumonia. The mean VDI score was 0.6 in the last visit. Nine (32.1%) patients had at least one damage item at the end of follow-up period. 
Our results showed that approximately one fifth of patients with adult IgA Vasculitis had relapses during follow-up. At the end of follow-up, one third of patients had at least one damage item. Although, 45% of patients had FFS≥1, the mortality rate was observed to be low in the present study. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.3865 
